


Solutions for Targeted Protein Degradation (TPD)




Enabling differentiated therapies

Excelra offers a unique portfolio of tailor-made analytical services and data to support your targeted protein degradation discovery and development programs

Our offerings


Degraders Intelligence Database (DID)

An intelligence database allowing its users to capture a snapshot of the competitive landscape in the degrader space to understand the companies working in the area and the strategies leveraged by them.



Degraders Discovery Database (D3)

Degrader Discovery Database is a comprehensive suite of compounds, ligases, drugs, and targets that provides a powerful data resource in various stages of degrader development for the entire drug discovery value chain.



Our data solutions are quite comprehensive in capturing relevant data points required for decision-making in the development of degrader. A few numbers are listed below:

Ligase	Target	Degrader	Disease
<ul style="list-style-type: none">• 500+ E3 ligases• 5 E1 ligases• 35+ E2 ligases	<ul style="list-style-type: none">• 1700+ targets• Ubiquitination sites	<ul style="list-style-type: none">• 20,000+ degraders• 900+ linkers• Solubility, permeability information	<ul style="list-style-type: none">• 250+ diseases• 10+ therapeutic areas



Our services

In addition to the data, we also offer a unique portfolio of tailor-made services to support your targeted protein degradation discovery and development programs.

E3 Ligase identification


Toolbox that identifies and shortlists novel E3 ligase which can be employed to design custom degraders



Cognate E1 & E2 partners



Expression & localization



Physiological targets

Target identification


Identify proteins which play a pivotal role in disease pathophysiology and are amenable for targeted ablation



Expression & localization



Physiological ligases



Ubiquitination sites and status

Disease prioritization

Identify right indications for a specific degrader of interest



Co-expressed target and ligases



Mechanism of Action elucidation



Role in disease pathophysiology

Value addition

Give your TPD research the Excelra edge

Expand the panel of E3 ligases, that can be exploited to design novel degraders


Identify the right target-ligase pair to expand the therapeutic potential

Identify the bonafide E1 & E2 partners for shortlisted E3 ligases to establish in-vitro ubiquitination assays


Expand portfolio by identifying right opportunities

Excelra advantage

Empowering you to discover new opportunities




Custom solutions




Global clientele



Advanced analytics



Domain expertise



Actionable insights

Unlock the hidden opportunities in targeted protein degradation space by visiting our website:
<https://www.excelra.com/discovery/targeted-protein-degradation/>



About Excelra

Excelra's data and analytics solutions empower innovation in life sciences across the value chain from discovery to market. The Excelra Edge comes from a seamless amalgamation of proprietary curated data assets, deep domain expertise and data science. The company's multifaceted teams harmonize and analyse large volumes of disparate unstructured data using cutting-edge technologies. We galvanize data-driven decisions to unlock operational efficiencies to accelerate drug discovery and development. Over the past 18 years, Excelra has been the preferred data and analytics partner to over 160 global clients, including 15 of the top 20 large Pharma companies.